Mazzariello Gina — SEC Form 4 filings
SEC reporting owner CIK 1913765. 21 Form 4 filings on record with FilingPulse; latest filed 2026-09-14.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2024-02-27 to 2026-09-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 18 legs across 15 filings — 134,267 shares, $1,613,964 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 9,525 shares @ $32.46 ($309,140) in Amylyx Pharmaceuticals, Inc., filed 2026-09-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Legal Officer | 21 | — | 18 legs · 134,267 sh · $1,613,964 | 10 |
Form 4 filings — Mazzariello Gina
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-14 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 9,525 @ $32.46 · Sale (S): 11 @ $33.34 | EDGAR |
| 2026-08-20 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 21,284 @ $0 | EDGAR |
| 2026-07-13 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 15,000 @ $18.32 · Sale (S): 15,000 @ $17.61 | EDGAR |
| 2026-03-09 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 74,660 @ $0 · Grant/award (A): 111,990 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 6,844 @ $14.52 | EDGAR |
| 2026-02-25 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 3,419 @ $14.14 | EDGAR |
| 2026-02-04 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 3,448 @ $14.65 | EDGAR |
| 2025-10-02 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 8,828 @ $14.58 | EDGAR |
| 2025-08-14 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 15,000 @ $8.07 · Sale (S): 15,000 @ $8.34 | EDGAR |
| 2025-05-27 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Gift (G): 1,000 @ $0 | EDGAR |
| 2025-04-02 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 9,192 @ $3.48 | EDGAR |
| 2025-03-10 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 63,851 @ $0 · Grant/award (A): 95,777 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 1,611 @ $3.12 | EDGAR |
| 2025-02-26 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 4,169 @ $3.15 | EDGAR |
| 2025-02-05 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 3,678 @ $3.49 | EDGAR |
| 2024-10-02 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 8,709 @ $3.20 | EDGAR |
| 2024-05-16 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 10,455 @ $1.88 | EDGAR |
| 2024-04-18 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 80,560 @ $0 · Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 1,540 @ $18.73 | EDGAR |
| 2024-02-28 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 36,667 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Sale (S): 2,838 @ $18.76 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1913765 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →